Clinical trial of HIV vaccine begins in United States and South Africa
Novel vaccine includes NIH-funded technology in development since 2004
2023-09-20
(Press-News.org) WHAT:
A trial of a preventive HIV vaccine candidate has begun enrollment in the United States and South Africa. The Phase 1 trial will evaluate a novel vaccine known as VIR-1388 for its safety and ability to induce an HIV-specific immune response in people. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has provided scientific and financial support throughout the lifecycle of this HIV vaccine concept and is contributing funding for this study.
VIR-1388 is designed to instruct the immune system to produce T cells that can recognize HIV and signal an immune response to prevent the virus from establishing chronic infection. VIR-1388 uses a cytomegalovirus (CMV) vector, meaning a weakened version of CMV delivers the HIV vaccine material to the immune system without causing disease in the study participants. CMV has been present in much of the global population for centuries. Most people living with CMV experience no symptoms and are unaware that they are living with the virus. CMV remains detectable in the body for life, which suggests it has the potential to deliver and then safely help the body retain HIV vaccine material for a long period, potentially overcoming the waning immunity observed with more short-lived vaccine vectors.
NIAID has funded the discovery and development of the CMV vaccine vector since 2004 and is funding this trial with the Bill & Melinda Gates Foundation and Vir Biotechnology, based in San Francisco. The trial is sponsored by Vir and conducted through the NIAID-funded HIV Vaccine Trials Network (HVTN) as study HVTN 142.
HVTN 142 is taking place at six sites in the United States and four in South Africa and will enroll 95 HIV-negative participants. Participants will be randomly assigned to one of four study arms: three arms will each receive a different dose of the vaccine, and one will receive a placebo. To optimize participant safety, this study will only enroll people already living with asymptomatic CMV. Initial results are expected in late 2024, and an optional long-term sub-study will continue to follow volunteers for up to three years after their first vaccine dose.
Additional information about the trial is available on ClinicalTrials.gov under study identifier NCT05854381.
WHO:
Carl Dieffenbach, Ph.D., Director of NIAID’s Division of AIDS, is available to discuss this research.
CONTACT:
To schedule interviews, please contact the NIAID News & Science Writing Branch, (301) 402-1663, NIAIDNews@niaid.nih.gov.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.
NIH...Turning Discovery Into Health®
END
ELSE PRESS RELEASES FROM THIS DATE:
2023-09-20
NEW YORK, NY – Sept. 20, 2023 – As cities brace for a confluence of flu, COVID-19, pneumonia, and RSV infections this fall, the American Thoracic Society announced that five new health systems have partnered with the Society to improve vaccination rates. Grady Health System (Atlanta, GA), Meharry Medical College (Nashville, TN), St. Luke’s Health System (Boise, ID), the University of Colorado (Aurora, CO), and Wayne Health (Detroit, MI) join the University of Arizona/ Banner Health, West Virginia University Hospitals, Inc., and San Francisco Health Network/ University of California to help identify barriers to vaccination and find ...
2023-09-20
Mount Sinai’s Department of Rehabilitation and Human Performance has announced a $6.2 million grant from the Steven & Alexandra Cohen Foundation. The grant will expand the Cohen Center for Recovery From Complex Chronic Illnesses (CoRE) to encompass research and clinical care beyond long COVID to include “long Lyme Disease/Lyme+” as well as other infection-associated complex chronic illnesses.
This funding will be used for new research programs focusing on understanding and highlighting the key similarities and differences between long COVID; long Lyme disease/Lyme+, a collection of infection-associated ...
2023-09-20
There is a growing interest in incorporating assistance from private citizens into scientific projects globally. Nonetheless, it seems that Anders P. Tøttrup, an Associate Professor at the Natural History Museum of Denmark, might become the world's first professor in Citizen Science.
Anders P. Tøttrup is a trained biologist and leads the section for Citizen Science projects at the Natural History Museum of Denmark. These projects involve scientific endeavours in which citizens are invited to assist in collecting and analyzing data. Now, the Museum is taking a step further as Anders P. Tøttrup enters a 'professor track.' The goal is ...
2023-09-20
PULLMAN, Wash. – The bright lights of big cities could be causing an evolutionary adaptation for smaller eyes in some birds, a new study indicates.
Researchers found that two common songbirds, the Northern Cardinal and Carolina Wren, that live year-round in the urban core of San Antonio, Texas, had eyes about 5% smaller than members of the same species from the less bright outskirts. Researchers found no eye-size difference for two species of migratory birds, the Painted Bunting and White-eyed Vireo, no matter which part of the city ...
2023-09-20
An upconversion organic light-emitting diode (OLED) based on a typical blue-fluorescence emitter achieves emission at an ultralow turn-on voltage of 1.47 V, as demonstrated by researchers from Tokyo Tech. Their technology circumvents the traditional high voltage requirement for blue OLEDs, leading to potential advancements in commercial smartphone and large screen displays.
Blue light is vital for light-emitting devices, lighting applications, as well as smartphone screens and large screen displays. However, it is challenging to develop efficient blue organic light-emitting diodes (OLEDs) ...
2023-09-20
A new longitudinal study published online in the International Journal of Chronic Obstructive Pulmonary Disease found that older adults with COPD had a heightened risk of depression during the early stages of the COVID-19 pandemic.
Researchers examined a sample of 875 individuals with COPD from the Canadian Longitudinal Study on Aging, a national study of Canadian older adults. Using longitudinal data, researchers were able to differentiate between 369 respondents with COPD who had a pre-pandemic history of depression and 506 respondents who had never experienced ...
2023-09-20
Recent evidence strongly implicates infection by the Epstein-Barr virus (EBV) as the trigger for development of multiple sclerosis (MS). An international research team is now gathering to unveil the role of EBV in the onset and progression of the MS disease.
The team has ambitious goals:
“We aim to find out why only a few EBV infected people develop MS, and define the underlying mechanism of this process”, explains the principal investigator (PI), Professor Kjell-Morten Myhr of the University of Bergen.
“Our research will also seek to investigate if targeting the EBV infection with antiviral treatments can improve the disease course or even stop ...
2023-09-20
In a recent randomized clinical trial of patients with fibromyalgia, cognitive-behavioral therapy (CBT)—which uses structured techniques to alter distorted thoughts and negative moods—was superior to a matched education treatment in reducing the interfering effects of pain and other aspects of fibromyalgia on daily living.
Within the group that received CBT in the trial, which is published in Arthritis & Rheumatology, improvements were at least partly attributable to reductions in what’s known as catastrophizing, a state comprised of cognitive and emotional processes such as helplessness, rumination, and magnification of ...
2023-09-20
The amino acid creatine is essential for muscle and brain health, and people commonly use creatine supplements to improve exercise performance and increase muscle mass. Results from a recent clinical trial published in Food Science & Nutrition indicate that dietary creatine may also benefit individuals experiencing post-COVID-19 fatigue syndrome (also known as long COVID).
In the trial, 12 people with post-COVID-19 fatigue syndrome were randomized to take a placebo or 4 grams of creatine monohydrate per day for ...
2023-09-20
Investigators recently studied several species of freshwater mussels, which are endangered and are especially sensitive to changes in water quality, to explore the ramifications of sea-level rise in coastal rivers. The research published in Environmental Toxicology and Chemistry determined the concentration of sea salt that would harm the viability of young mussels.
The study focused on the ecosystems along the southeastern US coast, where sea-level measurements have indicated rising waters from 2 to 6mm per year. By detailing the levels in which salt water is toxic to mussels at various life stages, the results can provide guidance for conservation programs ...
LAST 30 PRESS RELEASES:
[Press-News.org] Clinical trial of HIV vaccine begins in United States and South Africa
Novel vaccine includes NIH-funded technology in development since 2004
